No Data
No Data
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Express News | Quince Therapeutics: Expects Potential Nda Submission to FDA & Marketing Authorization Application Submission to EMA in 2026
Express News | Quince Therapeutics: Expects to Report Topline Results in Q4 of 2025
Express News | Quince Therapeutics Announces the Lancet Neurology Publication of Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (a-T)
Express News | Quince Therapeutics- Qtrly Reported a Net Loss of $27.7 Mln, or a Net Loss of $0.64 per Basic and Diluted Share